

Optifresh®
Soothing relief from dry eyes.

Available from
API, Symbion, Sigma & CH2
Always read the label and follow directions for use.

NOW BACK IN STOCK

Petrus

Today's issue of PD

Pharmacy Daily today features four pages of the latest news, including our **Beauty & Wellness** feature, plus a full page from **Pharmacy Hive**, and the **June Monthly MIMS Update**.

Nature's Own product recalls

THE Therapeutic Goods Administration has advised that Sanofi Consumer Healthcare is recalling Nature's Own Glucosamine Sulfate with Chondroitin batch 1662937 and Nature's Own Magnesium Glycinate 1150mg batch 1665576 due to the potential presence of a glass fragment within the bottles (not within the tablets).

Consumers have been advised to return products to the place of purchase for a refund - more **HERE**.

New cultural safety module

THE Pharmaceutical Society of Australia (PSA) has launched a new educational module designed to support community pharmacists in delivering culturally safe, responsive care for Aboriginal and Torres Strait Islander peoples.

Released as National Reconciliation Week came to a close, *Deadly pharmacists: Providing culturally safe and responsive care in community pharmacy* focuses on the unique role community pharmacists play in fostering equitable health outcomes for Aboriginal and Torres Strait Islander people and communities.

PSA national president, Professor Mark Naunton, said the new module represents an important step in supporting pharmacists to meet their professional responsibilities and contribute to positive health outcomes for First Nations Australians.

"We know pharmacists remain among the most accessible



healthcare professionals and continue to play a vital role in strengthening health equity for Aboriginal and Torres Strait Islander peoples," he said.

"This new module will help pharmacists to reflect on their practice, gain an understanding of the impacts of culture and history on health and wellbeing, and build meaningful relationships with their First Nations patients and communities.


"In doing so, pharmacists can help create environments where Aboriginal and Torres Strait Islander peoples feel respected, understood, and receive healthcare that they consider to be culturally safe."

Access the module **HERE**. *KB*

QSPP transition

AS QCPP transitions to QSPP, Pharmacy Hive has the resources, tools and guidance you need as community pharmacy enters a new era in quality and safety.

Learn more on **page five**.



Transform your Pharmacy

Dream It | Design It | Make It Happen

We design spaces which reflect the way you work, and create efficiencies throughout your pharmacy with particular emphasis on dispensary operations.

pharmacium.com.au
+613 9429 9244

PHARMACIUM

find out how we can help

Free naloxone dispensing machines rolled out in Victoria

THE Victorian Government has initiated a 12-month trial of naloxone dispensing machines across the state as part of a \$95 million statewide action plan to reduce drug harms and expand care.

There are 10 machines in metropolitan Melbourne and 10 in regional and rural communities, all accessible 24/7.

Each naloxone packet contains two nasal sprays with one dose

in each, as more than one dose is sometimes required to reverse a single overdose.

The naloxone nasal sprays are easy-to-use and come with clear instructions.

Dr Chris Alderman, pharmacist and board member of Harm Reduction Australia, said the group strongly supports the widest possible availability of naloxone products and welcomed the distribution through


vending machines.

"Far too many people are lost to overdoses, and enhanced access to naloxone for people using opioids - prescribed or otherwise - can help prevent tragedies," he told *Pharmacy Daily*.

"Pharmacists must continue to support naloxone availability, and can add value by providing quality evidence-based advice on opioid overdose prevention and response," he added.

Jext®
(adrenaline (epinephrine) acid tartrate)

Expanding options.
Increasing choice. ^{1,2}



PBS INFORMATION: This product is listed on the PBS. Refer to www.pbs.gov.au for full authority information



Review PI via the QR code before recommending Jext®. Safety information and references at www.jext.com.au/reference

TWC doubles retail media

TERRYWHITE Chemmart (TWC) will double its in-pharmacy digital screen network from 200 to 400 screens nationally, following strong campaign performance across its pharmacy network.


Recent in-store screen campaigns have delivered an average increase of 30% in sales, highlighting the growing role of pharmacy as a retail media channel, where brands can connect with customers close to the point of purchase.

"The expansion reflects what we're seeing across the market," said Janice Hoogveen, GM marketing and retail media at TWC.

"Brands are looking for retail media environments that deliver relevance, trust and measurable impact.

"Through TWC Connect, campaigns are supported by data and insights, helping brand partners deliver more targeted and meaningful messages," she continued.

"Pharmacy is uniquely powerful because customers arrive with purpose, seeking advice, treatment or solutions for themselves and their families," she concluded.



NSW med cannabis driving reforms

THE NSW Government will introduce laws to Parliament to ensure drivers taking prescribed medicinal cannabis containing THC will no longer automatically face charges under the current drug presence offence framework, following in the footsteps of Victoria and Tasmania.

To be eligible for the new system, drivers will be required to enrol as a registered medicinal cannabis user with Transport for NSW, provide proof of a valid prescription and complete an online education program about cannabis and driving safety.

Framed as a commonsense approach for people using lawfully prescribed medicinal cannabis while maintaining strong road safety protections, the government said the changes will be implemented cautiously, with strong safeguards and road safety protections built into every stage of the new system.

"This is a significant reform for NSW, but it's one we are approaching carefully and with road safety at the centre of every decision," said Premier Chris Minns.

"For thousands of people, medically prescribed cannabis is life-changing medication that is necessary for people to go about their daily lives.

"Our current laws enable people to safely and legally drive while taking a wide range of prescription medications but that doesn't include cannabis prescribed by a



medical practitioner.

"These changes strike a careful balance of providing a more practical approach for medicinal cannabis users while maintaining strong road safety protections for the community."

There are around one million medicinal cannabis users in Australia, and an estimated 300,000 in NSW.

Uniting has welcomed the announcement, with Uniting NSW. ACT's social justice lead Alexandra Hogan stating: "We need a health and wellbeing response to drug use, and that includes people who drive and use prescribed medicinal cannabis".

"Today's announcement is recognition that the NSW *Road Transport Act* needs to be amended to be in step with the current legal status of medicinal cannabis, and in line with laws for similar prescribed drugs," Hogan continued.

"If your work or daily life requires driving, the law as it stands is creating unfair barriers for people who use prescribed medicinal cannabis," she concluded. *KB*

APC acts on FDSV

AHPRA, National Boards, and Accreditation Authorities have issued a joint statement (available [HERE](#)) committing to building the health workforce's capability to recognise and respond to family, domestic and sexual violence (FDSV).

"Health practitioners are often the first - and sometimes the only - trusted professionals that victim-survivors can turn to for help," Ahpra CEO Justin Untersteiner said.

"Ensuring practitioners have the skills to recognise and respond to family, domestic and sexual violence safely and sensitively can make a real difference in the lives of victim-survivors."

Among the signatories is the Australian Pharmacy Council (APC), which has reaffirmed its commitment to strengthening professional capabilities, supporting education providers to embed relevant capability development, and working towards a coordinated, cross-sector response to the issue.

"Pharmacists are often on the frontline of care and may be among the first professionals individuals turn to for support," said APC CEO Bronwyn Clark.

"This joint statement reflects our shared commitment to ensuring graduates are prepared to recognise and respond to family, domestic and sexual violence with care, professionalism and compassion," she concluded. *KB*

Health Services

“More services & support.
Better access.
Stronger community care.”

Ruthanne Jaja, TerryWhite Chemmart, Macquarie Street



TerryWhite Chemmart.

Dedicated to Care

Editor's Choice: DermaAngel launches innovative addition to acne range

DERMAANGEL has released a new face and body mist to target acne breakouts all over the body, including hard-to-reach areas.

Designed for active lifestyles, the ultra-fine BHA Face and Body Acne Mist (RRP \$14.99) makes it easy to apply across the face, back and shoulders, and is formulated with a salicylic acid complex, using time-release microcapsule technology to penetrate pores, reduce congestion and prevent breakouts in the future.

Other ingredients include niacinamide to control excess oil and reduce inflammation, tranexamic acid to minimise redness and hyaluronic acid to rebalance hydration.

According to DermaAngel,



clinical testing has shown visible results in two weeks, with blackheads reduced by 14.3% and acne by 11.8%.

Available at pharmacies including Priceline, TerryWhite Chemmart, Direct Chemist Outlet, Chempro and Chemist Warehouse Online.

Luna repositions brand



AUSTRALIAN self-tan brand Luna Bronze is on a mission to reposition and reintroduce its skin-first brand in a saturated category, while changing consumer attitudes towards UV exposure.

"It's a highly saturated tanning market, with a lot of noise and strong loyalty to existing products," co-founders Rhiannon Hall and Maddy Balderson recently told *Retail Beauty*.

"There's also a broader cultural layer - a lot of the category locally is still tied to sun exposure and traditional tanning behaviours."

Education is core to the brand, which avoids promoting sun exposure or positioning tanning as an aspirational need.

"We're here to offer a safer, skin-first alternative for people who enjoy having a glow, and to help shift the conversation towards healthier choices."


Meanwhile, the brand is now focusing on continuing international expansion, following its recent launch into Ulta Beauty in the US earlier this year.

Luna Bronze is now stocked in more than 1,000 retail stores around the world, including 320 Priceline stores.

Food for the scalp

CALMERCEUTICALS' Hair Food is back after selling through yet another restock in under two weeks.

Developed to create visibly thicker, fuller and healthier hair, the scalp serum features key actives including peptides, caffeine, niacinamide, argan and rosemary oils, hyaluronic acid and panthenol.



Revlon releases smudgeproof tubing mascara



REVLON has released the new All In Tubing Mascara (RRP \$28), a smudgeproof mascara that creates dramatic and defined lashes.

Formulated with shea butter and castor oil, the mascara also conditions and hydrates lashes, while gliding on smoothly with a curved brush for precise application.

The product is available in black and brown, and thanks to the tubing formula is easy to remove with warm water.

Revlon also recently released the new Photoready Instant Blur Liner (RRP \$26), formulated with the brand's own blurring technology to create soft, full lips.

The creamy formula helps to smooth and reduce lines, creating an instant, soft-focus effect.

Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty & Wellness
by Pharmacy Daily

Dispensary Corner

US BASEBALL player Bryce Harper has turned heads over his unorthodox toothbrushing method.

In a TikTok video showing his morning routine, the Philadelphia Phillies star squeezed the toothpaste directly into his mouth rather than applying it on the brush.

The method sparked ridicule across the internet, no less from the American Dental Association, which advised against it.

"It is not suggested to do it that way," said Ohio dentist Andrew Zucker, a consumer advisor for the association.

"I don't think there's anything to be gained.

"The only thing to be lost is just wasting a whole bunch of toothpaste.

"Just put a little pea-sized bit of it on a toothbrush and that's all you need," Zucker added.

Maria Ryan, chief clinical officer at Colgate-Palmolive said that the biggest concern of this method is the risk of germs.

"When you're putting your mouth on the toothpaste tube, you get those germs on there.

"Sometimes people share toothpaste and things like that, so I worry about that a little bit."

Speaking on the video, Harper said that it's something that he's always done, but is happy that the video went viral regardless.

"If I help half a person a day, changing an ingredient or letting them know there are better quality products out there that they can use or that'll make them feel better, then I won that day."

LPG supporting country kids

LIFE Pharmacy Group (LPG) has joined efforts to improve children's healthcare in regional Australia by supporting the Royal Far West's Ride for Country Kids (RFCK) fundraising campaign.

LPG sponsored local Forbes cyclist Stuart Thomas for the journey across regional New South Wales, with this year's event raising a total of more than \$432,000 to deliver critical health services to children in need, and helping to improve their health and wellbeing.

"The work Royal Far West carries out in rural and regional areas is incredible, and we are very proud to support the Ride for Country Kids," Life Pharmacy Group CEO Michael Flannery said.

"Stu did a brilliant job to raise more than \$12,000.

"I was born and raised in Forbes, in the Central West of NSW, so I appreciate how isolating life in the country can be," Flannery continued.

"For kids facing developmental and mental challenges, the geographical distance can make it much harder to access the specialist support and services they need."

The RFCK raises funds and awareness for developmental, behavioural and mental health services for children in need in rural and remote areas.

This year's event saw almost 70 participants begin the three-day ride in Parkes, travelling through Manildra and Molong, visiting schools and communities in Trundle and Eugowra, before completing the ride in Forbes.

"Community is at the heart of all



we do in LPG so supporting this ride was a small way of showing our appreciation for the tremendous work of Royal Far West," concluded Flannery.

Thomas' fundraising page is [HERE](#).

Pictured: Michael Flannery, Stuart Thomas and Sarah Hazell, partner at Flannery's and Life Pharmacies.

Nominate mental health champions

THE Australian Mental Health Prize has opened nominations for its 2026 awards and is calling for Australians who have made outstanding contributions to mental health to be recognised for their leadership, advocacy, research and care.

A collaboration between UNSW Psychiatry & Mental Health, the Black Dog Institute and Neuroscience Research Australia (NeuRA), the prize celebrates those working to improve the mental health and wellbeing of Australians, or prevent or treat mental illness.

Now in its eleventh year, the awards recognise individuals and organisations across four categories: Aboriginal or Torres Strait Islander, Lived Experience, Professional, and Community Hero.

Nominations close Fri 31 Jul - learn more [HERE](#).

DID YOU KNOW?

That we regularly publish **Health Professional only** editions of *Pharmacy Daily*?

[CLICK HERE TO UPDATE YOUR DETAILS](#)




QSPP: A New Era for Quality and Safety in Community Pharmacy

Australian community pharmacy accreditation is entering its most significant period of change in almost three decades, with the transition from the Quality Care Pharmacy Program (QCPP) to the new Quality and Safety Pharmacy Program (QSPP) commencing from October 2026. While the foundations of quality accreditation remain firmly in place, the new program represents a substantial shift in how pharmacies demonstrate quality, safety and continuous improvement.

At its core, QSPP reflects the evolution of community pharmacy from a predominantly dispensing-focused profession to an increasingly clinical, patient-centred healthcare service. Accreditation will now be assessed against the Australian Community Pharmacy Standard AS85000:2024, which aligns closely with the National Safety and Quality Primary and Community Healthcare Standards. This alignment places community pharmacy within the broader national healthcare quality framework and reinforces its role as an integral part of Australia's primary healthcare system.

One of the most notable changes is the stronger emphasis on clinical governance, patient safety, consumer engagement and workforce capability. Rather than focusing primarily on whether policies and procedures exist, QSPP requires evidence that quality and safety systems are actively embedded in everyday pharmacy practice and are delivering positive outcomes for patients.

The accreditation framework itself has also been streamlined. The previous five QCPP domains have been replaced by four integrated domains: Clinical Governance and Leadership; Safely Delivering Medicines and Pharmacy Services; Partnering with Consumers and the Community; and Business Governance and Operations. This structure better reflects the interconnected nature of modern pharmacy practice and encourages a more holistic approach to quality management.

Assessment processes will also evolve. While on-site assessments remain a key component, pharmacies will be assessed through a tiered model based on the complexity of services they provide, ranging from general pharmacy practice through to full scope services and complex compounding. This approach is intended to ensure that assessment requirements are proportionate and relevant to each pharmacy's service profile. In addition, accreditation cycles will move from two years to three years, supported by a desktop (online) mid-



cycle review that promotes ongoing quality improvement rather than periodic compliance activity.

For pharmacy owners and managers, perhaps the greatest practical change will be in reporting, evidence recording and performance monitoring. The focus is shifting from collecting single point in time documents for assessment, towards demonstrating how quality and safety are embedded in the pharmacy's daily practice on a long-term basis, how risks are identified and managed, how incidents and feedback are used to drive improvement, and how quality and safety outcomes are measured over time. Pharmacies will increasingly need to show evidence of continuous improvement activities, engagement with patients in their own healthcare, and the effectiveness of governance systems.

While the transition will require preparation and a new way of thinking about accreditation, it also presents a significant opportunity. QSPP is designed to support high standards of healthcare practice, while strengthening confidence among patients, government and healthcare stakeholders.

Most importantly, it positions community pharmacy to support future scope-of-practice expansion and to continue its evolution as a trusted, accessible and high-quality primary healthcare destination for Australians.

Resources, tools, and guidance for your transition to QSPP

Pharmacy Hive was created by pharmacists for pharmacy and has been supporting pharmacies with QCPP resources, tools, and guidance for over 5 years.

Now we're here to support you in the major shift to QSPP:

- ✔ Compliant policies & procedures
- ✔ Automated recording, collation, & storage of evidence
- ✔ Team-ready tools
- ✔ Pre and post assessment support and advice



Pharmacy Hive
by pharmacists for pharmacy



Scan the QR code to be notified of upcoming webinars on the transition to QSPP and how Pharmacy Hive will help.



1300 598 884 | hello@pharmacyhive.au | pharmacyhive.au

New Products

- **Loncastuximab tesirine (Zynlonta)** is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal immunoglobulin G1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a pyrrolobenzodiazepine dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine is internalised followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. *Zynlonta monotherapy has provisional approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.* It is not indicated for patients with primary central nervous system lymphoma. Zynlonta powder for infusion contains loncastuximab tesirine 10 mg and is available in packs of 1 vial. Each vial contains 5 mg/mL of loncastuximab tesirine after reconstitution.
- **Pirtobrutinib (Jaypirca)** is a reversible, noncovalent inhibitor of Bruton's tyrosine kinase (BTK). BTK is a signalling protein of the B-cell antigen receptor and cytokine receptor pathways. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK as well as BTK harbouring C481 mutations leading to inhibition of BTK kinase activity. *Jaypirca, as monotherapy, is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have been previously treated with a covalent BTK inhibitor.* Jaypirca tablets contain pirtobrutinib 50 mg or 100 mg and are available in packs of 30 (50 mg) or 60 (100 mg).

New Presentation

- **Sildenafil (citrate) (Azulvig)** is now available as an oral suspension containing sildenafil 12.5 mg per 1 actuation (0.5 mL). The suspension has a total volume of 30 mL and is available in packs of 1 bottle.

New Indications

- **Lurbinectedin (Zepzelca)** in combination with atezolizumab, is now indicated for the maintenance treatment of extensive-stage small cell lung cancer (SCLC) in adult patients whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
- **Meningococcal polysaccharide conjugate A, C, Y and W-135 vaccine (MenQuadfi)** is now indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W and Y.
- **Obinutuzumab (rch) (Gazyva)** is now indicated for the treatment of adult patients with active class III or IV, with or without concomitant class V, lupus nephritis (LN) who are receiving standard therapy.
- **Vutrisiran (sodium) (Amvuttra)** is now indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Safety Related Changes

- **Nirmatrelvir and ritonavir (Paxlovid)** is no longer contraindicated in patients with severe renal impairment.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.